Zoetis Inc. (ZTS) financials — revenue, cash, debt and margins

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $29.4B
P/E (TTM): 11.71
Price / sales: 3.08
EV / EBITDA: —
Price / book: 9.33

Cash flow

FCF yield: 7.9%
SBC-adjusted FCF yield: 7.6%
SBC impact: 4.1%
Stock compensation (TTM): $95M

Margins & growth

Profit margin: 27.5%
Operating margin: —
Quarterly revenue (year on year): -0.2%
Quarterly earnings (year on year): -4.8%

Balance sheet

Cash & investments: $1.7B
Debt: $9B
Net cash / (debt): -$7.4B

Where the revenue comes from

Parasiticides is 25% of revenue.

By product or service

Year to Dec 31, 2025 · $9.5B

Parasiticides25%
$2.3B+8.7% vs. a year earlier
Vaccines21%
$2B+7.2% vs. a year earlier
Dermatology19%
$1.8B+6.0% vs. a year earlier
Anti Infective Products11%
$1B-5.8% vs. a year earlier
Other Pharmaceuticals7%
$697M+5.9% vs. a year earlier
Swine5%
$466M-9.7% vs. a year earlier
Animal Health Diagnostics5%
$434M+12.4% vs. a year earlier
Fish3%
$286M+18.2% vs. a year earlier
Other Non Pharmaceuticals3%
$263M+4.0% vs. a year earlier
Contract Manufacturing and Human Health Diagnostics1%
$116M+45.0% vs. a year earlier
Manufactured Product Other1%
$88M+7.3% vs. a year earlier
Medicated Feed Additives0.29%
$27M-90.8% vs. a year earlier

By business segment

Year to Dec 31, 2025 · $9.4B

United States55%
$5.1B+0.5% vs. a year earlier
International45%
$4.3B+3.7% vs. a year earlier

By region

Year to Dec 31, 2025 · $9.4B

United States55%
$5.1B+0.5% vs. a year earlier
Other Emerging Markets10%
$913M+5.5% vs. a year earlier
Other Developed Markets7%
$641M+13.7% vs. a year earlier
Brazil4%
$393M-5.1% vs. a year earlier
Australia4%
$329M+3.1% vs. a year earlier
United Kingdom3%
$325M+3.5% vs. a year earlier
Canada3%
$290M+4.7% vs. a year earlier
Germany3%
$236M+4.9% vs. a year earlier
China2%
$227M-15.9% vs. a year earlier
France2%
$165M+5.8% vs. a year earlier
Mexico2%
$160M-5.3% vs. a year earlier
Japan2%
$154M+4.8% vs. a year earlier
Spain2%
$145M+11.5% vs. a year earlier
Chile1%
$139M+13.0% vs. a year earlier
Italy1%
$137M+6.2% vs. a year earlier

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$9.52BQ2 2026-0.1%

1Y: +1.49%2Y: +6.75%5Y: +28.40%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

$2.62BQ2 2026-1.3%27.5% of revenue

1Y: +0.96%2Y: +11.60%5Y: +37.04%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

27.5%Q2 2026-1.3%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

$2.32BQ2 2026+3.5%

1Y: +2.07%2Y: +10.13%5Y: +36.08%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

$6.07Q2 2026+0.3%

1Y: +5.38%2Y: +18.79%5Y: +52.13%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

430.46MQ2 2026-1.6%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

11.8xQ2 2026-38.9%

11.8x today · median 32.8x and range 11.8x–56.2x across the points shown, Q3 2021 to Q2 2026

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

About Zoetis Inc.

Ticker: ZTS
SEC classification: Pharmaceutical Preparations (2834)
Listed on: NYSE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Zoetis Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Gross Profit, R&D Expense, Operating Income, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Borrowings (total), and Dividends paid. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.